
|Articles|September 5, 2014
The Transatlantic Trade and Investment Partnership: From Hot TTIP to Oblivion?
Author(s)Reflector
Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies - and ease conditions for drug firms on both sides of the ocean.
Advertisement
Only a year ago, hopes were high of rapid progress towards a transatlantic trade deal that would boost the European and US economies - and ease conditions for drug firms on both sides of the ocean. TTIP, the Transatlantic Trade and Investment Partnership, was the hot tip for a 2014 success story. But as summer slides away and autumn beckons, the latest read-out of progress suggests that rather than remaining a hot tip, TTIP now risks being tipped into oblivion.
For the rest of this article,
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
2
The Evolving Relationship Between FDA and Biotech
3
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
4
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
5




